written on 06.03.2014

UPDATED: Endo finally wins a Low-T drug nod, but safety dispute could snarl its launch


For Endo's testosterone therapy Aveed, the third time wasn't the charm with the FDA–but the fourth time was. After a trio of rejections, the FDA has given the thumbs up to the Low-T drug, and the Malvern, PA-based company expects to launch it this month. But amid the safety questions surrounding testosterone drugs, doing so may not be so easy.